Avadel Pharmaceuticals plc (NASDAQ:AVDL) recently announced positive phase III trial results for its drug FT218 to treat excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. SanaCurrents forecast in September 2019 that Avadel’s pivotal phase III trial, called REST-ON, […]